H.C. Wainwright downgraded Taro Pharmaceutical to Neutral from Buy with a $43 price target after the company entered into a merger agreement with Sun Pharmaceutical for $43 per share. Transaction completion appears low-risk, the analyst tells investors in a research note. The firm expects the transaction to close smoothly.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TARO: